Treatment Pathway
Treatment of Polymyositis
Polymyositis is an inflammatory myopathy causing progressive proximal muscle weakness, elevated muscle enzymes, and abnormal electromyography. Unlike dermatomyositis, it lacks the characteristic skin findings; treatment includes corticosteroids and immunosuppressants.
ACR (American College of Rheumatology)EULAR (European League Against Rheumatism)BSR (British Society for Rheumatology)NICEOARSI (osteoarthritis)
Managing Polymyositis effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Polymyositis can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓Treat-to-target (T2T) strategy in RA and SpA: aim for remission or low disease activity
- ✓Disease-modifying antirheumatic drugs (DMARDs) initiated early in RA — methotrexate first-line
- ✓Biologic DMARDs (anti-TNF, anti-IL-6, JAK inhibitors) when csDMARD inadequate
- ✓Hydroxychloroquine and low-dose prednisolone for SLE; immunosuppressives for organ-threatening disease
- ✓Analgesia stepped approach: paracetamol → NSAIDs → opioids (short-term); topical agents in OA
What to Do Now
- Learn your personal risk factors for Polymyositis (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Polymyositis
- Use our AI symptom checker to assess whether your symptoms fit an early Polymyositis pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Polymyositis-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Non-Pharmacological Management
- •Physical therapy: joint protection, range-of-motion exercises, strengthening — essential in OA and RA
- •Weight management: reduces mechanical load on hips/knees; reduces systemic inflammation
- •Occupational therapy: joint protection aids, assistive devices, workplace adaptations
- •Hydrotherapy and aquatic exercise: low-impact joint rehabilitation in OA
- •Dietary: Mediterranean diet reduces RA disease activity; omega-3 supplementation may reduce inflammation
- •Smoking cessation: major independent risk factor for RA initiation and worse disease course
- •Sun protection in SLE (UV can trigger flares)
Treatment Goals
🎯Remission or low disease activity (DAS28 <2.6 or <3.2) in RA
🎯Prevention of joint damage: minimal erosion progression on X-ray/MRI
🎯Functional preservation: HAQ score improvement; work and activity maintenance
🎯Control of systemic manifestations: uveitis, enthesitis, skin in SpA/PsA
🎯Minimise corticosteroid dose and long-term toxicity
Monitoring Parameters
- ◆Disease activity scores: DAS28 (RA), BASDAI/ASDAS (SpA), SLEDAI (lupus) — at 1, 3, 6 months
- ◆Shared care monitoring for methotrexate: FBC, LFTs monthly × 6, then every 3 months
- ◆Anti-TNF monitoring: TB screening (IGRA) before initiation; LTBI prophylaxis if positive
- ◆Bone mineral density: DEXA scan at baseline and every 2 years on long-term corticosteroids
- ◆Anti-dsDNA and complement (C3/C4) in SLE flare surveillance
- ◆Opthalmology: hydroxychloroquine retinopathy screening annually after 5 years use
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Polymyositis — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Polymyositis combined with new relevant symptoms
- ⚠Sudden worsening of Polymyositis symptoms despite established treatment
Escalation Criteria
- →Inadequate response to methotrexate at 3 months → add hydroxychloroquine/sulfasalazine or switch to biologic
- →Lupus nephritis → high-dose prednisolone + mycophenolate or cyclophosphamide
- →Vasculitis with organ involvement → IV methylprednisolone + cyclophosphamide or rituximab
- →Septic arthritis: urgent joint aspiration + IV antibiotics; surgical washout if joint destruction
Special Populations
Pregnancy: methotrexate, leflunomide, mycophenolate contraindicated — switch before conception; hydroxychloroquine and sulfasalazine continued
Elderly: increased infection risk with immunosuppressives; bone protection mandatory with steroids
Children: paediatric rheumatology specialist; treat early to preserve growth and development
Vaccinations: ensure up to date (pneumococcal, influenza, shingles) before biologic initiation
Clinical Insights
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →